Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07275359 · ClinicalTrials.gov registry record · Phase 1

Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

A Phase 1 study, sponsored by Duke University.

Not yet
Registry status
Phase 1
Development phase
45
Enrollment target

NCT07275359: Clinical Trial Phase 1 study, sponsored by Duke University.

NCT07275359 is a Phase 1 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07275359, a Phase 1 study, has not yet begun recruiting, sponsored by Duke University.

NOT YET RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.

Primary Outcome

Enroll and retain ≥ 30 (66%) participants through 6 months study period

Interventions

  • DRUG Metformin

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2026-09-01
Est. Completion 2029-10-02
Phase Phase 1
Duke University

1,725 total trials

What is known before NCT07275359 opens enrollment

NCT07275359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.

NCT07275359 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07275359 about?

NCT07275359 is a clinical study titled "Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations". The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.

What is the current status of trial NCT07275359?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-09-01. Estimated completion is 2029-10-02.

What interventions are being tested in trial NCT07275359?

The interventions under investigation include: Metformin (DRUG).

Who is sponsoring clinical trial NCT07275359?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07275359's enrollment target sits among peer trials

45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07275359, the US trial registry maintained by the National Library of Medicine. NCT07275359 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.